2633 — Jacobson Pharma Income Statement
0.000.00%
Last trade - 00:00- HK$1.29bn
- HK$1.65bn
- HK$1.47bn
- 81
- 95
- 67
- 97
Annual income statement for Jacobson Pharma, fiscal year end - March 31st, HKD millions except per share, conversion factor applied.
2020 March 31st | 2021 March 31st | 2022 March 31st | R2023 March 31st | 2024 March 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | PRESS | PRESS |
| Standards: | IFRS | IFRS | IFRS | — | — |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 1,571 | 1,446 | 1,596 | 1,268 | 1,468 |
| Cost of Revenue | |||||
| Gross Profit | 690 | 561 | 621 | 539 | 620 |
| Selling / General / Administrative Expenses | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 1,253 | 1,190 | 1,335 | 954 | 1,135 |
| Operating Profit | 318 | 256 | 261 | 313 | 333 |
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | 263 | 221 | 231 | 250 | 255 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | 217 | 186 | 188 | 207 | 210 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Extraordinary Items | |||||
| Net Income | 216 | 174 | 178 | 251 | 267 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | 216 | 174 | 178 | 251 | 267 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | 0.105 | 0.065 | 0.094 | 0.097 | 0.109 |
| Dividends per Share |